Skip to main content
Top
Published in:

16-05-2024 | Chronic Kidney Disease | Review

Diagnosis and management of primary hyperoxalurias: best practices

Authors: Mini Michael, Elizabeth Harvey, Dawn S. Milliner, Yaacov Frishberg, David J. Sas, Juan Calle, Lawrence Copelovitch, Kristina L. Penniston, Jeffrey Saland, Michael J. G. Somers, Michelle A. Baum

Published in: Pediatric Nephrology | Issue 11/2024

Login to get access

Abstract

The primary hyperoxalurias (PH 1, 2, and 3) are rare autosomal recessive disorders of glyoxylate metabolism resulting in hepatic overproduction of oxalate. Clinical presentations that should prompt consideration of PH include kidney stones, nephrocalcinosis, and kidney failure of unknown etiology, especially with echogenic kidneys on ultrasound. PH1 is the most common and severe of the primary hyperoxalurias with a high incidence of kidney failure as early as infancy. Until the recent availability of a novel RNA interference (RNAi) agent, PH care was largely supportive of eventual need for kidney/liver transplantation in PH1 and PH2. Together with the Oxalosis and Hyperoxaluria Foundation, the authors developed a diagnostic algorithm for PH1 and in this report outline best clinical practices related to its early diagnosis, supportive treatment, and long-term management, including the use of the novel RNAi. PH1-focused approaches to dialysis and kidney/liver transplantation for PH patients with progression to chronic kidney disease/kidney failure and systemic oxalosis are suggested. Therapeutic advances for this devastating disease heighten the importance of early diagnosis and informed treatment.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M (2022) Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review. Am J Kidney Dis 79:717–727PubMedCrossRef Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M (2022) Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review. Am J Kidney Dis 79:717–727PubMedCrossRef
3.
go back to reference Danpure CJ, Jennings R (1986) Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett 201:20–24PubMedCrossRef Danpure CJ, Jennings R (1986) Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett 201:20–24PubMedCrossRef
4.
go back to reference Webster KE, Ferree PM, Holmes RP, Cramer SD (2000) Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2). Hum Genet 107:176–185PubMedCrossRef Webster KE, Ferree PM, Holmes RP, Cramer SD (2000) Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2). Hum Genet 107:176–185PubMedCrossRef
5.
go back to reference Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295PubMedPubMedCentralCrossRef Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295PubMedPubMedCentralCrossRef
6.
go back to reference Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B (2021) A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100:621–635PubMedCrossRef Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B (2021) A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100:621–635PubMedCrossRef
7.
go back to reference Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O, Cerkauskiene R, Ferraro PM, Groen LA, Gupta A, Knebelmann B, Mandrile G, Moochhala SS, Prytula A, Putnik J, Rumsby G, Soliman NA, Somani B, Bacchetta J (2023) Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol 19:194-211 Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O, Cerkauskiene R, Ferraro PM, Groen LA, Gupta A, Knebelmann B, Mandrile G, Moochhala SS, Prytula A, Putnik J, Rumsby G, Soliman NA, Somani B, Bacchetta J (2023) Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol 19:194-211
9.
go back to reference Sas DJ, Harris C, Milliner DS (2019) Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis 47:79–89PubMedCrossRef Sas DJ, Harris C, Milliner DS (2019) Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis 47:79–89PubMedCrossRef
10.
go back to reference Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani F, Milliner DS, Palsson R (2013) Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol 28:1923–1942PubMedPubMedCentralCrossRef Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani F, Milliner DS, Palsson R (2013) Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol 28:1923–1942PubMedPubMedCentralCrossRef
11.
go back to reference Edvardsson V, Sas D (2022) Urinary stone disease and nephrocalcinosis. In Emma F, et al (ed) Pediatric Nephrology, 8th edn. Springer, Cham Edvardsson V, Sas D (2022) Urinary stone disease and nephrocalcinosis. In Emma F, et al (ed) Pediatric Nephrology, 8th edn. Springer, Cham
12.
go back to reference Marangella M, Petrarulo M, Vitale C, Daniele PG, Sammartano S, Cosseddu D, Linari F (1991) Serum calcium oxalate saturation in patients on maintenance haemodialysis for primary hyperoxaluria or oxalosis-unrelated renal diseases. Clin Sci (Lond) 81:483–490PubMedCrossRef Marangella M, Petrarulo M, Vitale C, Daniele PG, Sammartano S, Cosseddu D, Linari F (1991) Serum calcium oxalate saturation in patients on maintenance haemodialysis for primary hyperoxaluria or oxalosis-unrelated renal diseases. Clin Sci (Lond) 81:483–490PubMedCrossRef
13.
go back to reference Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, Blank M, Yang S, Fargue S, Rumsby G, Groothoff J, Allain M, West M, Hollander K, Lowther WT, Lieske JC (2020) End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol 15:1056–1065PubMedPubMedCentralCrossRef Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, Blank M, Yang S, Fargue S, Rumsby G, Groothoff J, Allain M, West M, Hollander K, Lowther WT, Lieske JC (2020) End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol 15:1056–1065PubMedPubMedCentralCrossRef
14.
go back to reference Milliner DS, Cochat P, Hulton SA, Harambat J, Banos A, Dehmel B, Lindner E (2021) Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies. Pediatr Nephrol 36:1785–1793PubMedPubMedCentralCrossRef Milliner DS, Cochat P, Hulton SA, Harambat J, Banos A, Dehmel B, Lindner E (2021) Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies. Pediatr Nephrol 36:1785–1793PubMedPubMedCentralCrossRef
15.
go back to reference Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB (1999) Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 56:268–274PubMedCrossRef Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB (1999) Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 56:268–274PubMedCrossRef
16.
go back to reference Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, Gupta A, Bacchetta J, Groothoff J; OxalEurope Consortium/Erknet Guideline Workgroup On Hyperoxaluria (2023) Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol 38:625–634PubMedCrossRef Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, Gupta A, Bacchetta J, Groothoff J; OxalEurope Consortium/Erknet Guideline Workgroup On Hyperoxaluria (2023) Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol 38:625–634PubMedCrossRef
17.
go back to reference Sas DJ, Enders FT, Mehta RA, Tang X, Zhao F, Seide BM, Milliner DS, Lieske JC (2020) Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. Kidney Int 97:786–792PubMedCrossRef Sas DJ, Enders FT, Mehta RA, Tang X, Zhao F, Seide BM, Milliner DS, Lieske JC (2020) Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. Kidney Int 97:786–792PubMedCrossRef
18.
go back to reference Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR; American Urological Assocation (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324PubMedCrossRef Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR; American Urological Assocation (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324PubMedCrossRef
20.
go back to reference Cochat P, Groothoff J (2013) Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol 28:2273–2281PubMedCrossRef Cochat P, Groothoff J (2013) Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol 28:2273–2281PubMedCrossRef
21.
go back to reference Leumann E, Hoppe B, Neuhaus T (1993) Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 7:207–211PubMedCrossRef Leumann E, Hoppe B, Neuhaus T (1993) Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 7:207–211PubMedCrossRef
22.
go back to reference Meschi T, Maggiore U, Fiaccadori E, Schianchi T, Bosi S, Adorni G, Ridolo E, Guerra A, Allegri F, Novarini A, Borghi L (2004) The effect of fruits and vegetables on urinary stone risk factors. Kidney Int 66:2402–2410PubMedCrossRef Meschi T, Maggiore U, Fiaccadori E, Schianchi T, Bosi S, Adorni G, Ridolo E, Guerra A, Allegri F, Novarini A, Borghi L (2004) The effect of fruits and vegetables on urinary stone risk factors. Kidney Int 66:2402–2410PubMedCrossRef
23.
go back to reference Massey L (2005) Magnesium therapy for nephrolithiasis. Magnes Res 18:123–126PubMed Massey L (2005) Magnesium therapy for nephrolithiasis. Magnes Res 18:123–126PubMed
24.
go back to reference Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS; OxalEurope (2012) Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27:1729–1736PubMedCrossRef Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS; OxalEurope (2012) Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27:1729–1736PubMedCrossRef
25.
go back to reference Noori N, Honarkar E, Goldfarb DS, Kalantar-Zadeh K, Taheri M, Shakhssalim N, Parvin M, Basiri A (2014) Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis 63:456–463PubMedCrossRef Noori N, Honarkar E, Goldfarb DS, Kalantar-Zadeh K, Taheri M, Shakhssalim N, Parvin M, Basiri A (2014) Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis 63:456–463PubMedCrossRef
26.
go back to reference Singh P, Chebib FT, Cogal AG, Gavrilov DK, Harris PC, Lieske JC (2020) Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (atypical). Kidney Int Rep 5:955–958PubMedPubMedCentralCrossRef Singh P, Chebib FT, Cogal AG, Gavrilov DK, Harris PC, Lieske JC (2020) Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (atypical). Kidney Int Rep 5:955–958PubMedPubMedCentralCrossRef
27.
go back to reference Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, Rumsby G; OxalEurope Consortium (2014) Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86:1197–1204PubMedCrossRef Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, Rumsby G; OxalEurope Consortium (2014) Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86:1197–1204PubMedCrossRef
28.
go back to reference Fargue S, Rumsby G, Danpure CJ (2013) Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 1832:1776–1783PubMedCrossRef Fargue S, Rumsby G, Danpure CJ (2013) Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 1832:1776–1783PubMedCrossRef
29.
go back to reference Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van’t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators (2021) Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med 384(13):1216–1226. https://doi.org/10.1056/NEJMoa2021712. PMID: 33789010CrossRefPubMed Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van’t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators (2021) Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med 384(13):1216–1226. https://​doi.​org/​10.​1056/​NEJMoa2021712. PMID: 33789010CrossRefPubMed
30.
go back to reference Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P; study collaborators (2021) Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clin J Am Soc Nephrol 16:1025–1036PubMedPubMedCentralCrossRef Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P; study collaborators (2021) Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clin J Am Soc Nephrol 16:1025–1036PubMedPubMedCentralCrossRef
31.
go back to reference Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I, Sellier-Leclerc AL, Lu J, Seddighzadeh A, Habtemariam B, McGregor TL, Fujita KP, Frishberg Y; ILLUMINATE-B Workgroup (2022) Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. Genet Med 24:654–662PubMedCrossRef Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I, Sellier-Leclerc AL, Lu J, Seddighzadeh A, Habtemariam B, McGregor TL, Fujita KP, Frishberg Y; ILLUMINATE-B Workgroup (2022) Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. Genet Med 24:654–662PubMedCrossRef
32.
go back to reference Hayes W, Sas DJ, Magen D, Shasha-Lavsky H, Michael M, Sellier-Leclerc AL, Hogan J, Ngo T, Sweetser MT, Gansner JM, McGregor TL, Frishberg Y (2023) Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. Pediatr Nephrol 38:1075–1086PubMedCrossRef Hayes W, Sas DJ, Magen D, Shasha-Lavsky H, Michael M, Sellier-Leclerc AL, Hogan J, Ngo T, Sweetser MT, Gansner JM, McGregor TL, Frishberg Y (2023) Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. Pediatr Nephrol 38:1075–1086PubMedCrossRef
33.
go back to reference Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D (2023) Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial. Am J Kidney Dis 81(2):145-155.e1PubMedCrossRef Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D (2023) Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial. Am J Kidney Dis 81(2):145-155.e1PubMedCrossRef
34.
go back to reference Stokes F, Acquaviva-Bourdain C, Hoppe B, Lieske JC, Lindner E, Toulson G, Vaz FM, Rumsby G (2020) Plasma oxalate: comparison of methodologies. Urolithiasis 48:473–480PubMedPubMedCentralCrossRef Stokes F, Acquaviva-Bourdain C, Hoppe B, Lieske JC, Lindner E, Toulson G, Vaz FM, Rumsby G (2020) Plasma oxalate: comparison of methodologies. Urolithiasis 48:473–480PubMedPubMedCentralCrossRef
35.
go back to reference Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830 Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830
36.
go back to reference Derveaux T, Delbeke P, Walraedt S, Raes A, Van Laecke S, Leroy BP, De Zaeytijd J (2016) Detailed clinical phenotyping of oxalate maculopathy in primary hyperoxaluria type 1 and review of the literature. Retina 36:2227–2235PubMedCrossRef Derveaux T, Delbeke P, Walraedt S, Raes A, Van Laecke S, Leroy BP, De Zaeytijd J (2016) Detailed clinical phenotyping of oxalate maculopathy in primary hyperoxaluria type 1 and review of the literature. Retina 36:2227–2235PubMedCrossRef
37.
go back to reference Lagies R, Beck BB, Hoppe B, Sreeram N, Udink Ten Cate FE (2013) Apical sparing of longitudinal strain, left ventricular rotational abnormalities, and short-axis dysfunction in primary hyperoxaluria type 1. Circ Heart Fail 6:e45–e47PubMedCrossRef Lagies R, Beck BB, Hoppe B, Sreeram N, Udink Ten Cate FE  (2013) Apical sparing of longitudinal strain, left ventricular rotational abnormalities, and short-axis dysfunction in primary hyperoxaluria type 1. Circ Heart Fail 6:e45–e47PubMedCrossRef
38.
go back to reference Sas DJ, Enders FT, Gunderson TM, Mehta RA, Olson JB, Seide BM, Banks CJ, Dehmel B, Pellikka PA, Lieske JC, Milliner DS (2021) Natural history of clinical, laboratory, and echocardiographic parameters of a primary hyperoxaluria cohort on long term hemodialysis. Front Med (Lausanne) 8:592357PubMedCrossRef Sas DJ, Enders FT, Gunderson TM, Mehta RA, Olson JB, Seide BM, Banks CJ, Dehmel B, Pellikka PA, Lieske JC, Milliner DS (2021) Natural history of clinical, laboratory, and echocardiographic parameters of a primary hyperoxaluria cohort on long term hemodialysis. Front Med (Lausanne) 8:592357PubMedCrossRef
39.
go back to reference Fisher D, Hiller N, Drukker A (1995) Oxalosis of bone: report of four cases and a new radiological staging. Pediatr Radiol 25:293–295PubMedCrossRef Fisher D, Hiller N, Drukker A (1995) Oxalosis of bone: report of four cases and a new radiological staging. Pediatr Radiol 25:293–295PubMedCrossRef
40.
go back to reference Ben-Shalom E, Cytter-Kuint R, Rinat C, Becker-Cohen R, Tzvi-Behr S, Goichberg J, Peles V, Frishberg Y (2021) Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study. Pediatr Nephrol 36:3123–3132PubMedCrossRef Ben-Shalom E, Cytter-Kuint R, Rinat C, Becker-Cohen R, Tzvi-Behr S, Goichberg J, Peles V, Frishberg Y (2021) Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study. Pediatr Nephrol 36:3123–3132PubMedCrossRef
41.
go back to reference Julian BA, Faugere MC, Malluche HH (1987) Oxalosis in bone causing a radiographical mimicry of renal osteodystrophy. Am J Kidney Dis 9:436–440PubMedCrossRef Julian BA, Faugere MC, Malluche HH (1987) Oxalosis in bone causing a radiographical mimicry of renal osteodystrophy. Am J Kidney Dis 9:436–440PubMedCrossRef
42.
go back to reference Rootman MS, Mozer-Glassberg Y, Gurevich M, Schwartz M, Konen O (2018) Imaging features of primary hyperoxaluria. Clin Imaging 52:370–376PubMedCrossRef Rootman MS, Mozer-Glassberg Y, Gurevich M, Schwartz M, Konen O (2018) Imaging features of primary hyperoxaluria. Clin Imaging 52:370–376PubMedCrossRef
43.
go back to reference El Hage S, Ghanem I, Baradhi A, Mourani C, Mallat S, Dagher F, Kharrat K (2008) Skeletal features of primary hyperoxaluria type 1, revisited. J Child Orthop 2:205–210PubMedPubMedCentralCrossRef El Hage S, Ghanem I, Baradhi A, Mourani C, Mallat S, Dagher F, Kharrat K (2008) Skeletal features of primary hyperoxaluria type 1, revisited. J Child Orthop 2:205–210PubMedPubMedCentralCrossRef
44.
go back to reference Merz LM, Born M, Kukuk G, Sprinkart AM, Becker I, Martin-Higueras C, Hoppe B (2023) Correction to: three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. Pediatr Nephrol 38:2497–2498PubMedCrossRef Merz LM, Born M, Kukuk G, Sprinkart AM, Becker I, Martin-Higueras C, Hoppe B (2023) Correction to: three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. Pediatr Nephrol 38:2497–2498PubMedCrossRef
45.
go back to reference Merz LM, Born M, Kukuk G, Sprinkart AM, Becker I, Martin-Higueras C, Hoppe B (2023) Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. Pediatr Nephrol 38:2083–2092PubMedCrossRef Merz LM, Born M, Kukuk G, Sprinkart AM, Becker I, Martin-Higueras C, Hoppe B (2023) Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. Pediatr Nephrol 38:2083–2092PubMedCrossRef
46.
go back to reference Bacchetta J, Fargue S, Boutroy S, Basmaison O, Vilayphiou N, Plotton I, Guebre-Egziabher F, Dohin B, Kohler R, Cochat P (2010) Bone metabolism in oxalosis: a single-center study using new imaging techniques and biomarkers. Pediatr Nephrol 25:1081–1089PubMedCrossRef Bacchetta J, Fargue S, Boutroy S, Basmaison O, Vilayphiou N, Plotton I, Guebre-Egziabher F, Dohin B, Kohler R, Cochat P (2010) Bone metabolism in oxalosis: a single-center study using new imaging techniques and biomarkers. Pediatr Nephrol 25:1081–1089PubMedCrossRef
47.
go back to reference Tonnelet D, Benali K, Rasmussen C, Goulenok T, Piekarski E (2020) Diffuse hypermetabolic bone marrow infiltration in severe primary hyperoxaluria on FDG PET. Clin Nucl Med 45(6):e296–e298PubMedCrossRef Tonnelet D, Benali K, Rasmussen C, Goulenok T, Piekarski E (2020) Diffuse hypermetabolic bone marrow infiltration in severe primary hyperoxaluria on FDG PET. Clin Nucl Med 45(6):e296–e298PubMedCrossRef
48.
go back to reference Bacchetta J, Boivin G, Cochat P (2016) Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol 31:1–6PubMedCrossRef Bacchetta J, Boivin G, Cochat P (2016) Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol 31:1–6PubMedCrossRef
49.
go back to reference Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67:1704–1709PubMedCrossRef Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67:1704–1709PubMedCrossRef
50.
go back to reference Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS (2014) Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant 14:1433–1438PubMedPubMedCentralCrossRef Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS (2014) Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant 14:1433–1438PubMedPubMedCentralCrossRef
51.
go back to reference Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC; Rare Kidney Stone Consortium (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570PubMedPubMedCentralCrossRef Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC; Rare Kidney Stone Consortium (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570PubMedPubMedCentralCrossRef
52.
go back to reference Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, Gupta A, Bacchetta J, Groothoff J; OxalEurope Consortium/Erknet Guideline Workgroup On Hyperoxaluria (2022) Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol 38:625-634 Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, Gupta A, Bacchetta J, Groothoff J; OxalEurope Consortium/Erknet Guideline Workgroup On Hyperoxaluria (2022) Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol 38:625-634
53.
go back to reference Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH (1994) Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 331:1553–1558PubMedCrossRef Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH (1994) Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 331:1553–1558PubMedCrossRef
54.
go back to reference Berini SE, Tracy JA, Engelstad JK, Lorenz EC, Milliner DS, Dyck PJ (2015) Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. Muscle Nerve 51:449–454PubMedPubMedCentralCrossRef Berini SE, Tracy JA, Engelstad JK, Lorenz EC, Milliner DS, Dyck PJ (2015) Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. Muscle Nerve 51:449–454PubMedPubMedCentralCrossRef
55.
go back to reference Biebuyck N, Destombes C, Prakash R, Boyer O (2023) Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi? J Nephrol 36:1473–1476PubMedCrossRef Biebuyck N, Destombes C, Prakash R, Boyer O (2023) Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi? J Nephrol 36:1473–1476PubMedCrossRef
56.
go back to reference Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, Tönshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B; PHYOX2 study investigators (2023) PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int 103:207–217 Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, Tönshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B; PHYOX2 study investigators (2023) PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int 103:207–217
57.
go back to reference Martin-Higueras C, Feldkötter M, Hoppe B (2021) Is stiripentol truly effective for treating primary hyperoxaluria? Clin Kidney J 14:442–444PubMedCrossRef Martin-Higueras C, Feldkötter M, Hoppe B (2021) Is stiripentol truly effective for treating primary hyperoxaluria? Clin Kidney J 14:442–444PubMedCrossRef
58.
go back to reference Martinez-Turrillas R, Martin-Mallo A, Rodriguez-Diaz S, Zapata-Linares N, Rodriguez-Marquez P, San Martin-Uriz P, Vilas-Zornoza A, Calleja-Cervantes ME, Salido E, Prosper F, Rodriguez-Madoz JR (2022) CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria. Mol Ther Methods Clin Dev 25:137–146PubMedPubMedCentralCrossRef Martinez-Turrillas R, Martin-Mallo A, Rodriguez-Diaz S, Zapata-Linares N, Rodriguez-Marquez P, San Martin-Uriz P, Vilas-Zornoza A, Calleja-Cervantes ME, Salido E, Prosper F, Rodriguez-Madoz JR (2022) CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria. Mol Ther Methods Clin Dev 25:137–146PubMedPubMedCentralCrossRef
59.
go back to reference Sellier-Leclerc AL, Metry E, Clave S, Perrin P, Acquaviva-Bourdain C, Levi C, Crop M, Caillard S, Moulin B, Groothoff J, Bacchetta J (2023) Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases. Nephrol Dial Transplant 38:517–521PubMedCrossRef Sellier-Leclerc AL, Metry E, Clave S, Perrin P, Acquaviva-Bourdain C, Levi C, Crop M, Caillard S, Moulin B, Groothoff J, Bacchetta J (2023) Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases. Nephrol Dial Transplant 38:517–521PubMedCrossRef
60.
go back to reference Breeggemann MC, Gluck SL, Stoller ML, Lee MM (2023) A case report of kidney-only transplantation in primary hyperoxaluria type 1: a novel approach with the use of nedosiran. Case Rep Nephrol Dial 13:63–69PubMedPubMedCentralCrossRef Breeggemann MC, Gluck SL, Stoller ML, Lee MM (2023) A case report of kidney-only transplantation in primary hyperoxaluria type 1: a novel approach with the use of nedosiran. Case Rep Nephrol Dial 13:63–69PubMedPubMedCentralCrossRef
61.
go back to reference Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS; Investigators of Rare Kidney Stone Consortium (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11:119–126PubMedCrossRef Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS; Investigators of Rare Kidney Stone Consortium (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11:119–126PubMedCrossRef
62.
go back to reference Shah RJ, Vaughan LE, Enders FT, Milliner DS, Lieske JC (2020) Plasma oxalate as a predictor of kidney function decline in a primary hyperoxaluria cohort. Int J Mol Sci 21:3608 Shah RJ, Vaughan LE, Enders FT, Milliner DS, Lieske JC (2020) Plasma oxalate as a predictor of kidney function decline in a primary hyperoxaluria cohort. Int J Mol Sci 21:3608
63.
go back to reference Watts RW, Veall N, Purkiss P (1984) Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci (Lond) 66:591–597PubMedCrossRef Watts RW, Veall N, Purkiss P (1984) Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci (Lond) 66:591–597PubMedCrossRef
64.
go back to reference Marangella M, Cosseddu D, Petrarulo M, Vitale C, Linari F (1993) Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria. Nephrol Dial Transplant 8:1333–1337PubMed Marangella M, Cosseddu D, Petrarulo M, Vitale C, Linari F (1993) Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria. Nephrol Dial Transplant 8:1333–1337PubMed
65.
go back to reference Marangella M, Petrarulo M, Cosseddu D, Vitale C, Linari F (1992) Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis 19:546–553PubMedCrossRef Marangella M, Petrarulo M, Cosseddu D, Vitale C, Linari F (1992) Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis 19:546–553PubMedCrossRef
66.
go back to reference Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF (2006) Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70:1642–1648PubMedCrossRef Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF (2006) Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70:1642–1648PubMedCrossRef
67.
go back to reference Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F (2017) Impact of regular or extended hemodialysis and hemodialfiltration on plasma oxalate concentrations in patients with end-stage renal disease. Kidney Int Rep 2:1050–1058PubMedPubMedCentralCrossRef Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F (2017) Impact of regular or extended hemodialysis and hemodialfiltration on plasma oxalate concentrations in patients with end-stage renal disease. Kidney Int Rep 2:1050–1058PubMedPubMedCentralCrossRef
68.
go back to reference Franssen CF (2005) Oxalate clearance by haemodialysis–a comparison of seven dialysers. Nephrol Dial Transplant 20:1916–1921PubMedCrossRef Franssen CF (2005) Oxalate clearance by haemodialysis–a comparison of seven dialysers. Nephrol Dial Transplant 20:1916–1921PubMedCrossRef
69.
go back to reference Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC (2015) Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int 87:623–631PubMedCrossRef Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC (2015) Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int 87:623–631PubMedCrossRef
70.
go back to reference Díaz C, Catalinas FG, de Alvaro F, Torre A, Sánchez C, Costero O (2004) Long daily hemodialysis sessions correct systemic complications of oxalosis prior to combined liver-kidney transplantation: case report. Ther Apher Dial 8:52–55PubMedCrossRef Díaz C, Catalinas FG, de Alvaro F, Torre A, Sánchez C, Costero O (2004) Long daily hemodialysis sessions correct systemic complications of oxalosis prior to combined liver-kidney transplantation: case report. Ther Apher Dial 8:52–55PubMedCrossRef
71.
go back to reference Plumb TJ, Swee ML, Fillaus JA (2013) Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria. Am J Kidney Dis 62:1155–1159PubMedCrossRef Plumb TJ, Swee ML, Fillaus JA (2013) Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria. Am J Kidney Dis 62:1155–1159PubMedCrossRef
72.
go back to reference Yamauchi T, Quillard M, Takahashi S, Nguyen-Khoa M (2001) Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1. Nephrol Dial Transplant 16:2407–2411PubMedCrossRef Yamauchi T, Quillard M, Takahashi S, Nguyen-Khoa M (2001) Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1. Nephrol Dial Transplant 16:2407–2411PubMedCrossRef
73.
go back to reference Tang X, Voskoboev NV, Wannarka SL, Olson JB, Milliner DS, Lieske JC (2014) Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am J Nephrol 39:376–382PubMedCrossRef Tang X, Voskoboev NV, Wannarka SL, Olson JB, Milliner DS, Lieske JC (2014) Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am J Nephrol 39:376–382PubMedCrossRef
74.
go back to reference Cochat P, Fargue S, Harambat J (2010) Primary hyperoxaluria type 1: strategy for organ transplantation. Curr Opin Organ Transplant 15:590–593PubMedCrossRef Cochat P, Fargue S, Harambat J (2010) Primary hyperoxaluria type 1: strategy for organ transplantation. Curr Opin Organ Transplant 15:590–593PubMedCrossRef
75.
go back to reference Cornell LD, Amer H, Viehman JK, Mehta RA, Lieske JC, Lorenz EC, Heimbach JK, Stegall MD, Milliner DS; Rare Kidney Stone Consortium Primary Hyperoxaluria (RKSC PH) investigators (2022) Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: incidence, risk factors, and effect on renal allograft function. Am J Transplant 22:85–95PubMedCrossRef Cornell LD, Amer H, Viehman JK, Mehta RA, Lieske JC, Lorenz EC, Heimbach JK, Stegall MD, Milliner DS; Rare Kidney Stone Consortium Primary Hyperoxaluria (RKSC PH) investigators (2022) Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: incidence, risk factors, and effect on renal allograft function. Am J Transplant 22:85–95PubMedCrossRef
76.
go back to reference Villani V, Gupta N, Elias N, Vagefi PA, Markmann JF, Paul E, Traum AZ, Yeh H (2017) Bilateral native nephrectomy reduces systemic oxalate level after combined liver-kidney transplant: a case report. Pediatr Transplant 21(3). Villani V, Gupta N, Elias N, Vagefi PA, Markmann JF, Paul E, Traum AZ, Yeh H (2017) Bilateral native nephrectomy reduces systemic oxalate level after combined liver-kidney transplant: a case report. Pediatr Transplant 21(3).
77.
go back to reference Mor E, Nesher E, Ben-Ari Z, Weissman I, Shaharabani E, Eizner S, Solomonov E, Rahamimov R, Braun M (2013) Sequential liver and kidney transplantation from a single living donor in two young adults with primary hyperoxaluria type 1. Liver Transpl 19:646–648PubMedCrossRef Mor E, Nesher E, Ben-Ari Z, Weissman I, Shaharabani E, Eizner S, Solomonov E, Rahamimov R, Braun M (2013) Sequential liver and kidney transplantation from a single living donor in two young adults with primary hyperoxaluria type 1. Liver Transpl 19:646–648PubMedCrossRef
78.
go back to reference Metry EL, van Dijk LMM, Peters-Sengers H, Oosterveld MJS, Groothoff JW, Ploeg RJ, Stel VS, Garrelfs SF (2021) Transplantation outcomes in patients with primary hyperoxaluria: a systematic review. Pediatr Nephrol 36:2217–2226PubMedPubMedCentralCrossRef Metry EL, van Dijk LMM, Peters-Sengers H, Oosterveld MJS, Groothoff JW, Ploeg RJ, Stel VS, Garrelfs SF (2021) Transplantation outcomes in patients with primary hyperoxaluria: a systematic review. Pediatr Nephrol 36:2217–2226PubMedPubMedCentralCrossRef
79.
go back to reference Xiang J, Chen Z, Xu F, Mei S, Li Z, Zhou J, Dong Y, Gu Y, Huang Z, Hu Z (2020) Outcomes of liver-kidney transplantation in patients with primary hyperoxaluria: an analysis of the scientific registry of transplant recipients database. BMC Gastroenterol 20:208PubMedPubMedCentralCrossRef Xiang J, Chen Z, Xu F, Mei S, Li Z, Zhou J, Dong Y, Gu Y, Huang Z, Hu Z (2020) Outcomes of liver-kidney transplantation in patients with primary hyperoxaluria: an analysis of the scientific registry of transplant recipients database. BMC Gastroenterol 20:208PubMedPubMedCentralCrossRef
80.
go back to reference Dhondup T, Lorenz EC, Milliner DS, Lieske JC. (2018) Combined liver-kidney transplantation for primary hyperoxaluria type 2: a case report. Am J Transplant 18:253–257PubMedCrossRef Dhondup T, Lorenz EC, Milliner DS, Lieske JC. (2018) Combined liver-kidney transplantation for primary hyperoxaluria type 2: a case report. Am J Transplant 18:253–257PubMedCrossRef
81.
go back to reference Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS; IPHR Investigators (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493–2501PubMedPubMedCentralCrossRef Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS; IPHR Investigators (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493–2501PubMedPubMedCentralCrossRef
82.
go back to reference Devresse A, Cochat P, Godefroid N, Kanaan N (2020) Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep 5:2136–2145PubMedPubMedCentralCrossRef Devresse A, Cochat P, Godefroid N, Kanaan N (2020) Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep 5:2136–2145PubMedPubMedCentralCrossRef
83.
go back to reference Lee E, Ramos-Gonzalez G, Rodig N, Elisofon S, Vakili K, Kim HB (2018) Bilateral native nephrectomy to reduce oxalate stores in children at the time of combined liver–kidney transplantation for primary hyperoxaluria type 1. Pediatr Nephrol 33:881–887 Lee E, Ramos-Gonzalez G, Rodig N, Elisofon S, Vakili K, Kim HB (2018) Bilateral native nephrectomy to reduce oxalate stores in children at the time of combined liver–kidney transplantation for primary hyperoxaluria type 1. Pediatr Nephrol 33:881–887
Metadata
Title
Diagnosis and management of primary hyperoxalurias: best practices
Authors
Mini Michael
Elizabeth Harvey
Dawn S. Milliner
Yaacov Frishberg
David J. Sas
Juan Calle
Lawrence Copelovitch
Kristina L. Penniston
Jeffrey Saland
Michael J. G. Somers
Michelle A. Baum
Publication date
16-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 11/2024
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-024-06328-2

Other articles of this Issue 11/2024

Pediatric Nephrology 11/2024 Go to the issue